Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Overview of Harvard Bioscience (HBIO)
Harvard Bioscience, Inc. is a global leader in the development, manufacturing, and marketing of specialized scientific instruments and technologies that empower advancements in life sciences research. The company provides essential tools and platforms that enable preclinical testing, drug discovery, and fundamental biological research. With a diverse portfolio of products, Harvard Bioscience serves pharmaceutical companies, biotechnology firms, academic institutions, and government laboratories worldwide. Its solutions are instrumental in fields such as neuroscience, toxicology, organoid research, and preclinical drug development.
Core Business and Product Offerings
The company’s product portfolio is designed to address the complex needs of life science researchers. Key offerings include:
- Ponemah™ Data Management Platform: A GLP-compliant, integrated solution for preclinical data collection, analysis, and reporting. This platform supports telemetry systems like the SoHo™ implantable telemetry solution and the VivaMARS™ activity monitoring system.
- Mesh Microelectrode Array (MEA) Platform: An advanced tool for real-time electrophysiology measurements within organoids, supporting applications in neuroscience, safety pharmacology, and toxicology.
- Behavioral Analysis Tools: Systems like VivaMARS™ provide high-throughput, automated solutions for behavioral testing in neuropharmacology and neurotoxicology research.
- Patch Clamp and Electrophysiology Systems: Cutting-edge instruments for in-vitro and in-vivo neuroscience research, enabling precise studies of ion channels, neural activity, and more.
Harvard Bioscience’s products are distributed through direct sales, online platforms, and partnerships with leading distributors such as Thermo Fisher Scientific and VWR. The company’s brands, including Harvard Apparatus, DSI, Buxco, and Multichannel Systems, are recognized for their reliability and innovation in the scientific community.
Global Presence and Market Reach
Headquartered in Holliston, Massachusetts, Harvard Bioscience operates across North America, Europe, and China, with manufacturing facilities in the United States, the United Kingdom, Germany, and Spain. Its products are sold in over 100 countries, reflecting a strong global footprint. Key markets include pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic institutions conducting cutting-edge research in life sciences.
Competitive Positioning
Harvard Bioscience differentiates itself through its focus on integrated solutions that streamline research workflows and enhance data quality. Its platforms, such as Ponemah, combine hardware and software to deliver comprehensive, GLP-compliant solutions for preclinical testing. The company’s emphasis on emerging fields like organoid research and machine learning-based data analysis positions it as a forward-thinking player in a competitive landscape. While it faces competition from larger corporations like Thermo Fisher Scientific and GE Healthcare, Harvard Bioscience’s niche focus and continuous innovation provide a competitive edge.
Significance in the Life Sciences Industry
Harvard Bioscience plays a critical role in advancing scientific discovery and therapeutic development. Its tools and technologies enable researchers to conduct sophisticated experiments with precision and efficiency, contributing to breakthroughs in areas like neuroscience, toxicology, and drug development. By addressing the evolving needs of the scientific community, Harvard Bioscience supports the acceleration of life-saving therapies and innovations in healthcare.
Conclusion
Harvard Bioscience, Inc. is a cornerstone in the life sciences ecosystem, providing indispensable tools and technologies that drive research and innovation. Its commitment to quality, innovation, and customer-centric solutions ensures its continued relevance in a dynamic and demanding industry.
Harvard Bioscience (Nasdaq: HBIO) will announce its third-quarter financial results on November 3, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. Eastern Time to discuss the results. Interested parties can join the call by dialing 1 (877) 303-7611 (toll-free) or 1 (970) 315-0445 (international), using conference ID # 8391005. Additionally, a live webcast will be available on the company's website, where the earnings release and presentation will also be accessible.
Harvard Bioscience, Inc. (Nasdaq: HBIO) reported a 25% year-over-year revenue growth for Q2 2021, reaching $29.2 million, driven by strong demand in pre-clinical and Cellular and Molecular (CMT) products, which grew by 20% and 22%, respectively. Despite higher global supply chain costs affecting operating margins, adjusted operating margins remained robust at 14.6%. Looking ahead, the company anticipates a 12% to 15% revenue growth for the fiscal year. Operating income was impacted, showing a loss per share of $(0.01), with adjusted diluted EPS at $0.06.
Harvard Bioscience (Nasdaq: HBIO) will release its financial results for Q2 2021 on August 5, 2021, prior to market opening. The announcement will be followed by a conference call at 8:00 a.m. ET, accessible via toll-free number 1 (877) 303-7611 or international number 1 (970) 315-0445, with conference ID # 6293853. The call will also be webcast through the Harvard Bioscience website. The results and accompanying slide presentation will be available on the Investor Relations section of their site.
Harvard Bioscience (Nasdaq: HBIO) reported a revenue increase of 14% for Q1 2021, totaling $27 million, driven by strong pre-clinical product demand which rose 24%. This growth follows continued momentum from Q4 2020, aided by effective sales strategies and improved academic lab sales. The operating loss improved significantly, with adjusted operating income reaching $3.2 million and an adjusted operating margin of 12%. The company expects revenue growth of 10% to 14% for 2021, indicating a positive outlook for future business performance.
Harvard Bioscience (Nasdaq: HBIO) will announce its Q1 2021 financial results on May 6, 2021, before market opening. A conference call will follow at 8:00 a.m. ET for discussions on the earnings report. Investors can participate by calling toll-free 1 (877) 303-7611 or internationally at 1 (970) 315-0445, using conference ID # 5876756. The call will also be available via webcast on Harvard Bioscience's website. The company specializes in technologies and products for research and drug development, serving a global client base.
Harvard Bioscience reported Q4 2020 revenue of $31.0 million, returning to pre-COVID levels, aided by a 19% year-over-year increase in preclinical product revenue. Operating income rose to $2.8 million, with a GAAP operating margin of 8.9%. The company successfully refinanced its credit facility, expected to save approximately $3 million annually in interest. For 2021, Harvard anticipates revenue growth of 8% to 12% and adjusted operating margins in the mid-to-upper teens, driven by new products and improved profit mix.
Harvard Bioscience (Nasdaq: HBIO) will release its fourth-quarter financial results for the period ending December 31, 2020, before the market opens on March 10, 2021. A conference call will be held that same day at 8:00 a.m. Eastern Time to discuss the results, accessible via toll-free and international numbers. The call will also be available through a live webcast on the company's website, where financial information including the earnings release and presentation slides will be published.
Harvard Bioscience (Nasdaq: HBIO) has successfully closed a new $65 million credit facility, refinancing existing debt to enhance liquidity and reduce borrowing costs. This refinancing will yield over $2 million in annual cash interest savings starting in 2021 while providing greater operational flexibility through less restrictive covenants. The facility includes a $40 million term loan and a $25 million senior revolving credit line, aimed at supporting the company's transition into a profitable growth platform.
Harvard Bioscience (Nasdaq: HBIO) will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference on November 18, 2020. CEO Jim Green and CFO Michael Rossi will engage in virtual meetings throughout the day. Interested investors can schedule a meeting by contacting their Benchmark representative or directly reaching out to Vince Curatola. Presentation materials will be available on the company’s investor relations page that same day at 8:00 AM ET. Harvard Bioscience specializes in technologies for drug development and serves a wide range of global customers.
Harvard Bioscience (Nasdaq: HBIO) reported Q3 2020 financial results showing improved operating income and reduced net debt year-over-year. Revenue rose sequentially to $24.0 million, supported by demand from CRO/pharma and the reopening of academic labs. Adjusted operating income was $3.6 million, with an operating margin of 14.8%. The company anticipates continued growth, forecasting mid to upper teen operating margins for the second half of 2020, driven by disciplined cost management and targeted investments.
FAQ
What is the current stock price of Harvard Biosci (HBIO)?
What is the market cap of Harvard Biosci (HBIO)?
What does Harvard Bioscience specialize in?
Who are the primary customers of Harvard Bioscience?
What are the key products offered by Harvard Bioscience?
How does Harvard Bioscience differentiate itself in the market?
Where does Harvard Bioscience operate?
What industries does Harvard Bioscience serve?
What is the significance of the Ponemah™ platform?
What is the focus of Harvard Bioscience's organoid research tools?
